Ampio Pharmaceuticals, Inc.
| NYSE MKT: AMPE
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company, which focuses on the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation, sexual dysfunction and CNS disease. The company intends to maintain a diversified product candidate pipeline to mitigate risks associated with pharmaceutical development which capitalizes on its internal discoveries and intellectual property, which includes owned and assigned patents, filed patent applications, exclusive licenses, and trade secrets and know-how, some of which may be the subject of future patent applications. Its intellectual property focuses on three primary areas: new indications for previously approved drugs, New Molecular Entities, and rapid point-of-care tests for diagnosis, monitoring and screening. Ampio was founded by Michael Macaluso in March 2008 and is headquartered in Greenwood Village, CO.